Literature DB >> 2482527

[Medical treatment of inoperable malignant glioma. Non-superselective intra-arterial chemotherapy with HECNU followed by conventional radiotherapy].

J Chiras1, F Fauchon, M Poisson, C Debussche, L Chauveinc, Y Pereon, R A Guérin, J Bories.   

Abstract

Forty-six cases of non-surgical malignant glioma were treated by several repeated infusion of non-superselective intra-arterial chemotherapy using HECNU, followed by conventional radiotherapy. Chemotherapy was well tolerated immediately. Good responses rate was 46% for the whole group, but was higher in anaplastic astrocytomas (71%) than in glioblastomas (43%). The median survival for responders was 17 months, and clinical improvement was observed in a large majority of them. Later, neurological or ophthalmological ipsilateral complications of varying severity were observed in 8.7% and 15% of the cases respectively. Despite these complications the treatment was generally well tolerated and gave in responders a longer survival with better comfort.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2482527

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  3 in total

1.  Intra arterial chemotherapy with ACNU and radiotherapy in inoperable malignant gliomas.

Authors:  L Chauveinc; M T Sola-Martinez; M Martin-Duverneuil; J J Mazeron; T Faillot; P Cornu; L Capelle; J Y Delattre; M Poisson; F Baillet; J Chiras
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

2.  Selective intra-arterial chemotherapy with BCNU in recurrent malignant gliomas.

Authors:  G B Bradac; R Soffietti; A Riva; G Stura; S Sales; D Schiffer
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

3.  Visual toxicity following intra-arterial chemotherapy with hydroxyethyl-CNU in patients with malignant gliomas. A prospective study with statistical analysis.

Authors:  G Defer; F Fauchon; M Schaison; J Chiras; P Brunet
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.